Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 11/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | SCN1A | P35498 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977640 | 0.89 | OPRM1 (0.38) | SLC6A9TSHRALDH1A1PRSS1PRSS2 | |
| Trifluoroacetic Acid SCHEMBL980207 | 0.88 | SLC6A9 (0.37) | SLC6A9TSHRALDH1A1PRSS1PRSS2 | |
| SCHEMBL977848 | 0.86 | KMT2A (0.37) | TSHRALDH1A1 | |
| SCHEMBL12923328 | 0.86 | PRSS1 (0.38) | SLC6A9TSHRPRSS1PRSS2PRSS3 | |
| SCHEMBL982241 | 0.75 | OPRM1 (0.42) | PKMSCN1ASCN2ASCN3A | |
| SCHEMBL977961 | 0.74 | EPHX1 (0.41) | — | |
| SCHEMBL977801 | 0.73 | SPHK1 (0.46) | — | |
| Iodide SCHEMBL15590042 | 0.70 | CTDSP1 (0.34) | TSHRALDH1A1PRSS1PRSS2PRSS3 | |
| Trifluoroacetic Acid SCHEMBL979474 | 0.69 | ALDH1A1 (0.33) | ALDH1A1PRSS1PRSS2PRSS3TAAR1 | |
| Trifluoroacetic Acid SCHEMBL978104 | 0.68 | ALDH1A1 (0.35) | ALDH1A1PRSS1PRSS2PRSS3TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680282-B2 | Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-03-25 | — | — | US | disclosed |
| US-20110015174-A1 | CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015174-A1 | CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | SLC6A9 709/4885TSHR 4271/4885ALDH1A1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.